Takeda Pharmaceutical Company Limited (4502)
Leveraging AI-driven drug discovery to make progress in preclinical development (Buy)
Takeda (4502.JT)_Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually (StrongBuy)
Competitor to Takhzyro released in the US (Buy)
Takeda Pharmaceutical (4502 JP) - 26/3 Q1 results: Weak US market (Buy)
TAK-861: Rival drug meets primary endpoint in Phase 2 trial (Buy)
Two successful phase III trials for narcolepsy type 1 drug (Buy)
